Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH

[GlobeNewswire] – HASBROUCK HEIGHTS, N.J. — Nymox Pharmaceutical Corporation announced today that the last enrolled patient has completed participation in the Company’s pivotal Phase 3 clinical trial, NX02-0018. The NX02-0018 … more

View todays social media effects on NYMX

View the latest stocks trending across Twitter. Click to view dashboard

See who Nymox is hiring next, click here to view